BioNTech Results Presentation Deck
Acquisition strengthens individualized 10 pipeline
ā
Multiple individualized therapy approaches to address wide range of Solid Tumors indications.
iNeST: Individualized
mRNA cancer vaccine
Uses patient's cancer
mutations to generate
neoantigen specific CD4+ and
CD8+ T cell responses in vivo
Early-stage / Adjuvant
stage cancers
41
liO, immuno-oncology; PBMC, peripheral blood mononuclear cell;
iNeST: partnered with Genentech/Roche
NEOSTIM individualized
neoantigen-T cell
therapy
Patient's PBMCs used to
induce and expand multiple
CD4+ and CD8+ neoantigen
T cell populations ex-vivo
CPI nonresponsive
tumors
Personalized TCR-T cell
therapy
Ex-vivo engineered neoantigen
specific TCR-T cell therapy
further strengthened by the
acquistion from Kite
Advanced tumors
BIONTECHView entire presentation